AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Oligonucleotide-based topical immunotherapy against HSV-2 has promise.(genital herpes treatment)
2003 JAN 9 - (NewsRx.com & NewsRx.net) -- Vaccinologists at the University of Texas say immunostimulatory sequence-containing oligonucleotides may have application as treatment for genital herpes.
"Synthetic oligonucleotides containing CpG motifs in specific sequence contexts have been shown to induce potent immune responses. We have evaluated mucosal administration of two immunostimulatory sequence (ISS)-containing phosphorothioate-stabilized oligonucleotides for antiherpetic efficacy in animal models," stated R.B. Pyles and colleagues.
"The ISS oligonucleotides, suspended in phosphate-buffered saline, were tested in mouse and guinea pig vaginal models of herpes simplex virus type 2 (HSV-2) infection. For comparison, groups of untreated, non-ISS oligonucleotide-treated, and acyclovir-treated animals also were monitored," explained the researchers.
Their "results indicated that vaginal epithelial application of ISS (up to 6 hours after viral inoculation) with mice lethally challenged with HSV-2 delayed disease onset and reduced the number of animals that developed signs of disease (p=0.003). ISS application significantly increased survival rates over those of controls (p=0.0014)," reported Pyles' group.
They said that "[t]he ISS also impacted an established infection in the guinea pig model of HSV-2 disease. A single administration of ISS (21 days after viral inoculation) significantly reduced the frequency and severity of HSV-2 lesions compared to results with ...
- Oligonucleotide-based topical immunotherapy against HSV-2 has promise.
- Newspaper article from: Immunotherapy Weekly January 8, 2003 700+ words
...guinea pig model of HSV-2 disease. A single administration of ISS (21 days after viral...frequency and severity of HSV-2 lesions compared to results with non-ISS oligonucleotide...mediated, since ISS had no direct effect on HSV-2 replication in...
- Oligonucleotide-based topical immunotherapy against HSV-2 has promise.(herpes...
- Newspaper article from: Virus Weekly January 7, 2003 700+ words
...guinea pig model of HSV-2 disease. A single administration of ISS (21 days after viral...frequency and severity of HSV-2 lesions compared to results with non-ISS oligonucleotide...mediated, since ISS had no direct effect on HSV-2 replication in...
- HSV-1 likely cause of new genital infections.(Infectious Diseases)(Herpes...
- Magazine article from: Internal Medicine News Mechcatie, Elizabeth November 15, 2005 700+ words
...vulvovaginal diseases. Young, sexually active women are more susceptible to HSV-1 because most do not have protective antibodies to HSV-1 due to the dramatic drop in childhood HSV-1 infections, said Dr. Hillier, director, reproductive infectious...
- HSV-2 underrecognized in HIV-positive patients: subclinical...
- Magazine article from: OB GYN News September 15, 2003 700+ words
...But it is now known that even asymptomatic HSV-2 infection can increase HIV transmissibility. "Both subclinical and clinical HSV-2 reactivation increase the frequency...a Seattle HIV clinic, 172 (70%) were HSV-2 seropositive; 42 had a history of symptomatic...
- HSV-2 Acquisition In Pregnancy High If Partner Infected: Partner testing is...
- Magazine article from: OB GYN News DeMott, Kathryn October 15, 2001 700+ words
...risk for contracting primary herpes simplex virus type 2 (HSV-2) infection, said Dr. Gardella of the University...to herpes but their partner was seropositive for either HSV-1, HSV-2, or both. Of the 125 women who were susceptible to...
- Vaccine prevents genital HSV infection in seronegative women but not in...
- Newspaper article from: Vaccine Weekly January 22, 2003 700+ words
...A vaccine containing the herpes simplex virus type 2 (HSV-2) glycoprotein-D-subunit and adjuvants was effective in preventing HSV infection in women who were seronegative for both HSV-1 and HSV-2 at baseline, according to a report in...
- Vaccine prevents genital HSV infection in seronegative women but not in...
- Magazine article from: Women's Health Weekly January 23, 2003 700+ words
...A vaccine containing the herpes simplex virus type 2 (HSV-2) glycoprotein-D-subunit and adjuvants was effective in preventing HSV infection in women who were seronegative for both HSV-1 and HSV-2 at baseline, according to a report in...
- Vaccine prevents genital HSV infection in seronegative women but not in men.
- Newspaper article from: Biotech Week January 22, 2003 700+ words
...A vaccine containing the herpes simplex virus type 2 (HSV-2) glycoprotein-D-subunit and adjuvants was effective in preventing HSV infection in women who were seronegative for both HSV-1 and HSV-2 at baseline, according to a report in...
Source: HighBeam Research, Oligonucleotide-based topical immunotherapy against HSV-2 has...